The role of atopy on cystic fibrosis (CF) progression remains unclear but evidence suggests that it may influence the appearance of co-morbid conditions such as CF asthma or allergic bronchopulmonary aspergillosis (ABPA). Recognising asthma in patients with CF is not always easy but the identification of atopic markers favours the diagnosis. Physicians should be aware of this fact in order to achieve a better control of respiratory symptoms in patients with CF. Bronchial mucosa inflammation and abnormal mucus predispose to mould colonisation. These patients are at higher risk of allergic sensitisation, especially when atopic susceptibility is present. In the particular case of A. fumigatus, allergic sensitisation precedes ABPA development, which occurs in up to 10% of CF patients. Progression of lung function deterioration is most strikingly pronounced in patients with ABPA. Therefore, sensitisation with A. fumigatus should be regularly tested in patients with CF, especially those at higher risk. Recombinant allergens constitute an important advance in differentiating Aspergillus sensitisation from ABPA itself.
Background
In the past, several reports have suggested an increased prevalence of atopy in cystic fibrosis (CF) patients compared to the general population. This was sustained by an increase in positive allergy skin prick tests, raised immunoglobulin E (IgE) and IgE antibodies in these patients. 1 The major allergic responses in CF patients are to Aspergillus fumigatus and to a lesser extent, other mould allergens such as Cladosporium herbarum and Alternaria alternate. [2] [3] [4] In more recent studies however, the sensitisation rate to conventional allergens such as house dust mite and grass pollen matches the common population. 2, 5 According to available data, prevalence of allergy in CF seems to increase progressively with age as well. 1 Historically, Lowe et al. established, in 1949 , that 30% of the relatives of CF patients had a clinical history of allergic disease. 6 Others studies reported a prevalence of allergy in patients with CF from 16 to 24%. 7, 8 A Mexican study involving 30 patients with CF showed that 26.6% had respiratory allergy, diagnosed on clinical and laboratory grounds. 9 About 40% had positive skin prick tests to at least one allergen, and that Aspergillus fumigatus (A. fumigatus) was the most frequently involved allergen (23% of the cases). 9 It is well known that a large number of patients with CF report symptoms that suggest an allergic type disorder, even without previous diagnosis of asthma, allergic rhinitis or eczema. 7 The coexistence of respiratory allergy in the form of bronchial asthma, allergic rhinitis or both is often present in CF. Recognising these diseases will contribute to a more global and proper approach of these patients with obvious improvement in their quality of life.
Although there is great controvery regarding the role atopy plays in CF, a deep knowledge is required on how the hypersensitivity phenomenon begins and how the immunoinflammatory response vicious circle can be controlled. This might lead to the development of new lung protection drugs and, thereafter, prolonged survival in these patients.
Cystic fibrosis
Cystic fibrosis (CF) is a well-characterised monogenic disease; it has an autosomal recessive inheritance pattern and is caused by a single-gene mutation on the CF transmembrane conductance regulator (CFTR). 10 It is relatively uncommon, although prevalence varies considerably depending on ethnicity and geography, and affects preferentially Caucasians of European descent 11 ; prevalence can reach as many as 1:2500 births among certain Caucasian groups. 12 The molecular mechanisms of the CF mutation have been well described in previous studies. A strong genotypephenotype correlation can be observed. A significant aIlelic heterogeneity exists, resulting in a continuum of disease expression varying from very mild to very severe. Different explanations have been proposed for such a wide spectrum of clinical manifestations. 13 These considerations are, nevertheless, beyond the scope of our review.
Inflammation is a cardinal feature of lung disease in CF. Although the primary genetic defect was detected in CF in 1989 14 and lung inflammation is ubiquitous in CF patients, we still know very little about how mutations in the CFTR gene are related to infection and inflammation. On the one hand, abnormal intracellular chloride retention and increased sodium reabsorption contribute to more viscous secretions which impair the mucociliary clearance. As a consequence, chronic colonisation by opportunistic pathogens, such as Staphylococcus aureus or Pseudomonas aeruginosa supervenes, leading to persistent inflammation and causing inexorably long-term lung destruction. On the other hand, lung inflammation can also precede lung infection. Even though the lungs are essentially normal at the time of birth, several studies have demonstrated inflammation and infectious changes before clinically evident lung disease is present, even in infancy. [15] [16] [17] The presence of high neutrophil counts, neutrophil elastase and inflammatory cytokines in broncho-alveolar lavage (BAL) specimens, obstructive mucous plugging and epithelial metaplasia has been reported, in young children with CF, even in the absence of positive microbiological cultures. 18 One can still suggest that organisms could be present in a number too small to appear on sputum cultures even though they are present in sufficient quantity to trigger an inflammatory response. Nevertheless, once bacterial clearance is usually reduced when inflammation is enhanced, the consequences of continuous inflammation due to the primary gene defect could well result in facilitated colonisation of the CF airways. 19, 20 Cystic fibrosis and asthma Cystic fibrosis and asthma are not always easily distinguished. Wheeze, whether in asthmatic or CF patients, involves airway mucosal oedema, mechanical obstruction by accumulated secretions, airway smooth muscle contraction, and dynamic collapse of airways.
It occurs frequently in both pathologies and for this reason it is difficult to determine which patients have concomitant asthma and which wheeze as a result of their underlying CF lung disease. However, it is important to readily recognise ''CF asthma'' once it can contribute to a better control of respiratory symptoms in patients with CF. It is clear from the North American Epidemiologic Study of Cystic Fibrosis (ESCF) that the diagnosis of asthma in CF does influence prescribing practice, in particular increasing the use of inhaled corticosteroids. 21, 22 There is, however, no consensus on how to define CF asthma. Acute airway obstruction reversed by bronchodilators, especially if seasonal or allergen induced, can be a valuable but fallible indicator, and laboratory data such as eosinophilia or high IgE levels, are also of limited value, as explained in later sections.
A personal history (eczema or allergic rhinitis) and a family history of atopy (including asthma) in first degree relatives are probably the most useful predictors of asthma. 23 Standard spirometric tests, although useful in assessing lung disease severity, are not reliable tools to diagnose asthma in CF patients. The reason for this apparent ineffectiveness of lung function testing in CF patients suspected of having asthma is the degree of variability in lung function measures. Forced expiratory volume in one second and forced vital capacity can vary as much as 15-20%, even when testing on the same day. 24, 25 Likewise, the role of bronchodilator responsiveness in patients with CF is not well defined and several studies report important limitations. 26, 27 CF patients often show a degree of bronchodilator responsiveness whether they have CF asthma or not. 28, 29 Bronchial hyperresponsiveness (BHR) is a typical finding in, but not exclusive to, asthma and even though it is also found in many CF patients, especially those with poorer lung function, the underlying mechanism is still debatable. 29, 30 Even the hypothesised role of atopy in ''CF asthma'' needs to be clarified. According to some studies, a strong association exists between atopy and BHR. 31, 32 Other authors, on the contrary, believe it might not be a significant risk factor for BHR development in patients with CF. [33] [34] [35] In a study with 20 children with CF, BHR was found to correlate with coexistent asthma, particularly for positive skin testing patients. 31 In a study by Eggleston et al., with CF patients with (20) and without (16) methacholine hyperreactivity, a significantly higher proportion of atopic patients was found in the first group, but no discriminative power between both groups was found for allergy history. 32 On the other hand, several other authors found BHR not conclusively associated with atopy, even though it is a common finding in CF patients. [33] [34] [35] Mitchell et al. performed methacholine challenges in 113 CF patients and found a positive response in 51% of the cases and asthma in 98% of those. However, there was no relationship between allergic rhinitis or positive allergen skin tests and positive methacholine response. 33 These findings are concordant with other studies, by Sanchez or ValverdeMolina with 22 and 32 patients, respectively, keeping this chapter still unfinished. 34, 35 According to Valverde-Molina et al., BHR may be associated with colonisation or infection with P. aeruginosa in patients with CF, and this may be a more important risk factor than atopy. 35 Once other causes of serum total IgE elevation are excluded, particularly allergic bronchopulmonary aspergillosis (ABPA), it can also constitute a guide to atopic status, strengthening the diagnosis of CF asthma in opposition to ''CF wheezers'' without asthma. 36 Atopy can also be confirmed through positive skin prick testing or serum specific IgE tests when common aeroallergens such as house dust mite, cat, dog, grass and tree pollens, are involved. On the other hand, as stated by Balfour-Lynn, a reaction to Aspergillus does not necessarily denote atopy, but this will be discussed later. 23 Nevertheless, a positive result would still support the diagnosis of CF asthma. 37 Asthma and CF differ not only clinically but in terms of immunopathology as well. In CF, it is mainly neutrophil driven, whilst in asthma it depends mostly on eosinophils and lymphocytes, with elevated exhaled nitric oxide levels; more severe forms of asthma, however, do tend to be associated with neutrophils. 38, 39 A Th2 balanced immune response is strongly characteristic of atopic asthma but, in general, CF does not quite fit into the Th1/Th2 pattern. 39 Patients with chronic Pseudomonas aeruginosa infection and ABPA also develop predominantly a Th2 type response. 40, 41 Chronic airway inflammation constitutes a determinant factor for BHR and, despite the similarities between the inflammation found in CF and asthma, immunopathological mechanisms are considerably different.
In the past, some authors also suggested a common genetic background linking asthma and CF, suggesting that atopy in CF patients could result from the same genetic defect responsible for CF. 42 Nevertheless, studies that tried to assess the association between asthma and CFTR gene mutations heterozygosity have led to conflicting results. In a study carried out in a Norway, no association was found between asthma and heterozygous CF. 43 A study from 2008 found that, although the relative risk of asthma did not differ between heterozygous CF and no heterozygous CF, the values of FEV1, and FEV1/FVC ratio were lower in carriers, suggesting that, according to pulmonary function testing, heterozygosity may be related with a silent obstructive pulmonary profile. 44 Using 15-year follow-up data from the Copenhagen City Heart Study, Dahl et al. found that CF DF508 heterozygotes may be overrepresented among individuals with asthma and may have poorer lung function than non-carriers. Furthermore, DF508 heterozygosity in context with familial predisposition to asthma may be associated with a greater annual FEV1 decline. 45 
Pathophysiology insights
In this section, the possible relationships between mould sensitisation, atopy and cystic fibrosis will be revised in a few words.
Cystic fibrosis patients show several risk factors which might influence atopic progression, such as increased permeability of the bronchial mucosa, 46 defective secretory IgA system 47 and entrapment of antigens in infected areas of the lungs 47 in association with ciliar dysfunction. 48 This would result in increased antigenic access through the tracheobronchial tree, favouring a constant stimulation of IgE production.
Under normal circumstances, despite high concentrations of exposure to mould spores, no sensitisation would occur. 49 This low sensitisation potential contrasts, however, with hyphal elements, significantly more allergenic. It has been known that exposure to high concentrations of hyphal elements, rather than spores, will have a chance of producing sensitisation. Spores are inhaled into the bronchial airway, becoming trapped in the luminal mucus of patients with progressively more severe airway inflammation.
In patients with CF, there will be enough time for spores to germinate, forming mycelia, with consequent release of allergenic proteins and sensitisation. 50, 51 Indeed, it is quite common to be able to culture Aspergillus fumigatus and observe hyphal networks in the sputum of CF patients, with up to 30% having positive cultures. 52 The sensitisation process occurs in genetically susceptible individuals and requires allergen processing by antigen presenting cells, which then stimulate T cells within the bronchoalveolar lymphoid tissue (BALT) in a Th2 balanced way.
Different theories have been proposed concerning the role of chronic P. aeruginosa colonisation in mould sensitisation and atopy. The highest IgE levels are associated with chronic Pseudomonas colonisation and frequent exacerbation of infection. These data have been used to suggest either that allergy contributes to the lung pathology or, alternatively, that serious lung infection facilitates allergen sensitisation.
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Aspergillus fumigatus
Special attention should be given to A. fumigatus, the most prevalent mould allergen identified in CF patients. 2 Colonisation of the lower respiratory tract with A. fumigatus is particularly frequent in patients with CF, with a reported incidence of 57%, 54 and a prevalence of 40%. 55 Aspergillus fumigatus, a widely distributed spore-bearing fungus, causes multiple diseases in humans, [56] [57] [58] such as invasive pulmonary aspergillosis, aspergilloma, and different forms of hypersensitivity diseases. These include allergic asthma, characterised by a Th2 response 59, 60 ; hypersensitivity pneumonitis, with Th1 response dominance, 61 and ABPA, which will be presented in later sections.
The immune response to A. fumigatus differs in atopic and non-atopic patients. In the first group a Th2 CD4þ T-cell response and IgE and IgG antibody responses prevail with a clinical spectrum of allergic sensitivity to ABPA and in nonatopic patients predominates a Th1 response. 60 The most common allergens include A. fumigatus and Aspergillus clavatus, but other species exist, causing mainly invasive disease.
Aspergillus has a very small spore size (3-5 mm), which enables it to penetrate deeply into the lung. Spores are capable of withstanding extraordinary atmospheric conditions (and suboptimal host defences). 62 As mycelia grow, it releases allergens that are processed by antigen-presenting cells bearing HLA-DR2 or -DR5. Proteases of A. fumigatus, with elastolytic and collagenolytic activities, may play a role facilitating antigen transport across the epithelial cell layer, by damaging the epithelial integrity and through direct interaction with epithelial cell surface receptors, resulting in production of proinflammatory cytokines and corresponding inflammatory responses. As previously explained, in susceptible individuals, the immune response to Aspergillus allergens becomes skewed toward a Th2 CD4þ cell response. 63 
ABPA
ABPA is a disease primarily occurring in patients with asthma (1%-2% of asthma patients) or with cystic fibrosis (1%-7.8% of CF patients). 60, [64] [65] [66] [67] [68] [69] [70] [71] ABPA is a lung disease caused by immediate hypersensitivity reaction against Aspergillus fumigatus. The most clinically relevant characteristics are impaired mucociliary clearance, mucoid impactions, wheezing, pulmonary infiltrates, bronchiectasis and fibrosis. 56 Some immunological manifestations include recurrent episodes of eosinophilic airways inflammation, peripheral blood eosinophilia, increased serum concentrations of IL-2 receptor, high total serum IgE levels, and increased circulating specific IgE and IgG against A. fumigatus antigen. 56, 72, 73 The pathophysiology of ABPA still remains largely speculative, nonetheless several predisposing factors have been proposed for ABPA development.
Familial occurrence of ABPA has been reported, suggesting a possible genetic contribution to the disease in CF. 74, 75 Firstly, Chauhan et al. suggested that Th2 reactivity to a major Aspergillus fumigatus antigen was restricted by HLA-DR2 or HLA-DR5 alleles. Later, the same authors concluded that HLA-DR molecules DR2, DR5, and possibly DR4 or DR7 contribute to susceptibility to ABPA, while HLA-DQ2 appears to be a protective factor. 76 In addition, there may be increased sensitivity of T cells, B cells, NK cells, and eosinophils to IL-4 stimulation due to mutations of IL-4R alpha and/or the Jak/STAT pathway genes. 77 The presence of IL-4R alpha single nucleotide polymorphisms, principally ile75val, appears to be a genetic risk for the development of ABPA. 78 This suggests a strong immunogenetic susceptibility in ABPA progression.
Likewise, CFTR mutation has also been implicated in the aetiology of ABPA 74 but no significant association with any particular CFTR genotype has been documented. 71, 79 Miller et al. found a higher incidence of ABPA among atopic patients with CF and an increased frequency of heterozygous mutations of the CFTR gene was identified in this group. 80 Patients with ABPA, but without CF, have been demonstrated to have higher frequencies of CFTR mutations as well. 80 This could probably be due to abnormal mucus production with spores trapping in the respiratory mucosa.
Atopy appears to be another important risk factor for ABPA. ABPA was diagnosed in 22% of atopic individuals with CF but in only 2% of non-atopic patients. 69 In another study, the majority of patients with ABPA were atopic, as defined by positive skin prick test to at least one common aeroallergen, other than A. fumigates. 67 Total IgE concentration was found to be increased in A. fumigatus sensitised patients with CF but with no ABPA. 68 All these data therefore suggest that atopy, especially in CF patients, may facilitate ABPA development.
Fungal colonisation and mycelia growth in CF has also been related to increased use of antibiotics for recurrent bacterial infections, facilitating A. fumigatus sensitisation and ABPA progression. 81 Although previous works detected no association between ABPA and P. aeruginosa colonisation. 82 Nikolaizik et al. reported a positive correlation between the two entities, suggesting that P. aeruginosa colonisation favours the process of A. fumigatus sensitisation. 83 The causal relationship between Aspergillus sensitisation and Pseudomonas colonisation has motivated great discussion over the years as it is difficult to disentangle the influences of the Pseudomonas from that of Aspergillus.
In vitro studies report a possible link between Aspergillus and Pseudomonas, as one of the major allergens of A. fumigatus is selectively released when Aspergillus is cocultured with Pseudomonas. This could explain the in vivo relationship between colonisation with these two organisms and the subsequent development of allergy.
Allergic sensitisation and clinical relevance
Sensitisation to A. fumigatus can be assessed by skin prick testing, a cheap, rapid, easy and highly sensitive screening test with high negative predictive value, or by a serological battery of assays with high specificity, but more expensive and less sensitive. 84 Sensitisation to A. fumigatus in CF has been reported to increase with age and to be as high as 56%. 85 When considering persistent asthma in west European countries, it is identified in 20%-25% of patients. 66, 86, 87 In other studies involving CF, 31-59% of patients were sensitised to A. fumigates.
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When considering CF and ABPA, although sensitisation to A. fumigatus is crucial to ABPA diagnosis, it is important to differentiate lung colonisation by Aspergillus (40%), 69 allergic sensitisation (20-60%), 66, 85 and clinically proven ABPA, a sizeable minority ranging from 1 to 11%. 71, 89 The evolution from simple sensitisation to ABPA constitutes a crucial phase which urges to be correctly diagnosed in order to prevent disease progression.
It has been proved that CF patients with A. fumigatus sensitisation and ''true'' ABPA differ in terms of specific IgE responses to recombinant allergens (rAspf1, rAspf2, rAspf3, rAspf4 and rAspf6). 90 A. fumigatus sensitised asthmatic patients react with 100% specificity and 88% sensitivity to rAspf1 and rAspf3, achieving positive and negative predictive values of 100% and 63% respectively, in terms of A. fumigatus sensitisation. 86 On the other hand, patients with ABPA present almost exclusively specific IgE to rAspf4 and rAspf6, suggesting that specific IgE to recombinant allergens of A. fumigatus could help in the early detection of sensitisation and ABPA itself. 86, 88 In terms of diagnostic specificity, recombinant allergens have proven superior to allergen extracts. 91 However, the relationship between A. fumigatus sensitisation and pulmonary function is still to be clarified. This issue has been studied by different groups, with conflicting results, 68, 71, 89, 92 thus reinforcing the need for adequate longitudinal studies aimed at establishing the effect of A. fumigatus sensitisation in the decline of pulmonary function, particularly in CF patients. Strong evidence exists that ABPA and bacterial infection or chronic colonisation are independently linked to a more rapid decline in lung function. Some authors even suggest that each entity may influence differently specific parameters of lung function testing but more research is required before any conclusions are stated. 79 
Conclusion
In conclusion, strong evidence exists that the atopic status may influence the appearance of co-morbid conditions in patients with CF, such as CF asthma, mould sensitisation and ABPA.
Cystic fibrosis patients appear to be more prone to mould sensitisation, in particular to A. fumigatus.
Age, bacterial lung colonisation, genetics and immunology appear to be important factors for mould sensitisation. The relationship between atopy and CF remains under scope but the immunoallergic evaluation assumes a great interest for a correct approach of these patients.
